Novavax inc (NVAX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating Activities:
Net loss

-132,694

-184,748

-183,769

-279,966

-156,937

-82,947

-51,983

-28,507

-19,364

-35,708

-40,346

Reconciliation of net loss to net cash used in operating activities:
Change in fair value of warrant liability

-

-

-

-

-

-

-267

-101

2,474

1,671

-1,972

Depreciation and amortization

5,676

8,159

9,817

8,505

5,983

4,424

2,591

1,666

1,613

1,372

1,194

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

222

Loss on disposal of property and equipment

-88

55

-269

-374

-681

-534

32

28

0

-35

-21

Gain on Catalent transaction

9,016

-

-

-

-

-

-

-

-

-

-

Non-cash impact of lease termination

-

-4,381

-

0

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

360

162

23

Amortization of net (discounts) premiums on marketable securities

-

-

-

-

-

-415

-507

18

-317

247

-

Amortization of debt issuance costs

1,424

1,424

1,424

1,305

0

0

-

-

-

-

147

Lease incentives received

-

-

-1,933

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

897

660

-

-

279

Lease incentives received

-

-

-

1,963

2,792

452

703

4,346

0

0

-

Non-cash stock-based compensation

17,048

18,314

19,809

19,160

13,431

6,090

2,480

2,091

2,047

1,339

1,533

Realized gains on marketable securities

-

-

-

-

-

615

0

879

0

0

-

Other

-4,869

2,396

-2,715

-663

-1,460

-60

200

0

341

282

-

Other non-cash income

-

-

-

-

-

-

-

-

0

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

36,204

-1,120

431

986

0

0

-

Net impairment of short-term investments

-

-

-

-

-

-

-

-

-

-

490

Accounts receivable

-

-

-

-

-

3,817

451

-954

1,911

-204

-32

Accounts receivable - unbilled

-

-

-

-

-

-

3,418

-266

1,836

0

-

Prepaid expenses and other assets

4,202

-1,212

-2,590

1,119

1,790

5,904

-402

-40

1,854

312

536

Accounts payable and accrued expenses

-11,485

-6,744

5,192

-4,808

9,075

13,979

4,184

2,009

-2,686

1,912

2,547

Deferred revenue

-8,331

-15,610

-4,456

-6,057

36,140

-253

-341

258

2,500

-150

150

Other liabilities

-

-

-

1,212

-721

-552

-

-

-

-

-

Net cash used in operating activities

-136,623

-184,825

-144,476

-258,768

-126,090

-67,014

-45,359

-18,229

-23,629

-32,852

-32,830

Investing Activities:
Capital expenditures

1,857

1,372

4,189

18,202

18,268

7,268

5,785

4,341

610

1,556

745

Proceeds from maturities of marketable securities

39,500

150,118

258,202

402,775

225,519

53,865

33,781

20,407

21,235

19,000

3,100

Proceeds from Catalent transaction

18,333

-

-

-

-

-

-

-

-

-

-

Proceeds from disposal of property and equipment

-

-

-

-

-

39

116

324

0

0

-

Net cash received from acquisition

-

-

-

-

-

-

3,034

0

0

-

-

Purchases of marketable securities

17,484

120,150

218,045

356,556

228,521

176,469

14,754

48,652

-

-

-

Purchases of investments

-

-

-

-

-

-

-

-

2,082

38,717

-

Net cash provided by (used in) investing activities

38,492

28,596

35,968

28,017

-21,270

-129,833

16,392

-32,262

18,543

-21,273

2,355

Financing Activities:
Principal payments of capital leases

-

-

37

71

67

124

87

104

0

0

-

Principal payments of notes payable

-

-

-

-395

-600

-671

-473

-60

-80

-86

-15,043

Proceeds from notes payable

-

-

-

-

-

-

1,450

650

0

0

-

Proceeds from settlement of notes receivable from former directors

-

-

-

-

-

-

-

-

50

0

-

Changes in restricted cash

-

-

-

-

-126

-2

-1

-756

0

0

-

Cash paid with acquisition

-

-

-

-

-

171

0

0

-

-

-

Proceeds from issuance of convertible notes

-

-

-

325,000

0

0

-

-

-

-

-

Payments of costs related to issuance of convertible notes

-

-

-

9,966

0

0

-

-

-

-

-

Payments for capped call transactions and costs

-

-

-

38,521

0

0

-

-

-

-

-

Net proceeds from sales of common stock

97,392

100,060

63,425

0

204,275

107,896

128,648

54,002

10,980

23,089

56,385

Proceeds from the exercise of stock options and employee stock purchases

992

2,745

1,152

3,802

4,801

2,789

1,498

54

179

426

952

Net cash provided by financing activities

98,384

102,805

64,540

279,849

208,283

109,717

131,035

53,786

11,129

23,429

42,294

Effect of exchange rate on cash, cash equivalents and restricted cash

-32

-48

142

-335

-

-

-

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

221

-53,472

-43,826

48,763

-

-

-

-

-

-

-

Effect of exchange rate on cash and cash equivalents

-

-

-

-

-150

-6

4

0

0

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

60,773

-87,136

102,072

3,295

6,043

-30,696

11,819

Supplemental disclosure of non-cash activities:
Settlement of notes receivable from former directors

-

-

-

-

-

-

-

-

1,522

0

-

Sale of common stock under the Sales Agreement not settled at year-end

497

-

-

-

-

-

-

-

847

0

-

Common stock issued in connection with acquisition

-

-

-

-

-

-

41,942

0

0

-

-

Conversion of convertible debt and accrued interest to common stock

-

-

-

-

-

-

-

-

-

-

7,660

Property and equipment purchases included in accounts payable and accrued expenses

49

519

15

697

2,797

2,615

379

1,321

14

418

66

Deposit applied towards the purchase of equipment

-

-

-

-

-

-

-

500

0

0

-

Equipment acquired under a capital lease

-

-

-

-

-

-

-

399

0

0

-

Supplemental disclosure of cash flow information:
Cash payments of interest

12,188

12,188

12,188

6,189

96

179

177

20

0

0

817